Key Takeaways Unique mRNA platform enables rapid market expansion and premium positioning in vaccines, with strong potential for high-margin, recurring revenues and first-mover advantages. Operational efficiency and breakthrough pipeline support sustainable growth, while industry trends drive significant partnering and shareholder value-creation opportunities.Read more
Key Takeaways Heavy reliance on a few clinical programs and uncertain commercialization timelines create considerable risk for sustained revenue and earnings growth. Elevated cash burn, history of losses, and potential delays in partnerships heighten the risk of future dilution or unprofitable expansion.Read more
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
